BLOG

Early-phase drug development is a complex process. Discover how Altasciences, as an integrated CRO/CDMO, alleviates the challenges and reduces risks.

Explore emerging areas of drugs from psychedelics and gene therapy, oligonucleotides to GLP-1RA for metabolic disorders.

Can the drug development industry change for the better? We dive into the obstacles and inefficiencies of the traditional outsourcing paradigm, and discuss how Altasciences offers an alternative to help sponsors safely accelerate their R&D.

Explore the significance of cytokines and the complement system, and the platforms Altasciences uses for monitoring and mitigating adverse effects.

This Q&A with Dr. Norbert Makori and Pierre Jolicoeur reveals insights on preclinical gene therapy studies and capabilities at Altasciences’ site in Seattle

Discover the inspiring journey of Altasciences’ Marta Rodriguez, Director of Clinical and Study Operations, who decided to pursue science after her parents fell ill.